The use of raloxifene in osteoporosis treatment

Bibliography

• D'Amelio P, Spertino E, Martino F, Isaia GC. Prevalence of post-menopausal osteoporosis in Italy and validation of decision rules for referring women for bone densitometry. Calcif Tissue Int 2013; in press; DOI: 10.1007/s00223-013-9699-5
   PubMed Web of Science ®Google Scholar
• Isaia GC, Braga V, Minisola S, Clinical characteristics and incidence of first fracture in a consecutive sample of post-menopausal women attending osteoporosis centers: the PROTEO-1 study. J Endocrinol Invest 2011;34:534-40
   PubMed Web of Science ®Google Scholar
• Gauthier A, Kanis JA, Jiang Y, Epidemiological burden of postmenopausal osteoporosis in the UK from 2010 to 2021: estimations from a disease model. Arch Osteoporos 2011;6:179-88
   PubMedGoogle Scholar
• Cooper C, Reginster JY, Cortet B, Long-term treatment of osteoporosis in postmenopausal women: a review from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF). Curr Med Res Opin 2012;28:475-91
   PubMed Web of Science ®Google Scholar
• Kanis JA, Burlet N, Cooper C, European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008;19:399-428
   PubMed Web of Science ®Google Scholar
• Corino A, D'Amelio P, Gancia R, Hypovitaminosis D in internal medicine inpatients. Calcif Tissue Int 2007;80:76-80
   PubMed Web of Science ®Google Scholar
• Black U, Jones CD, Falcone JF. Antagonism of estrogen action with a new benzothiophene derived antiestrogen. Life Sci 1983;32:1031-6
   PubMed Web of Science ®Google Scholar
• Miller MA, Katzenellenbogen BS. Characterization and quantitation of antiestrogen binding sites in estrogen receptor -positive and -negative human breast cancer cell lines. Cancer Res 1983;43:3094-100
   PubMed Web of Science ®Google Scholar
• Black LJ, Sato M, Rowley ER, Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 1994;93:63-9
   PubMed Web of Science ®Google Scholar
• Boss SM, Huster WJ, Neild J, Effects of raloxifene hydrochloride on the endometrium of postmenopausal women. Am J Obstet Gynecol 1997;177:1458-64
   PubMed Web of Science ®Google Scholar
• Delmas PD, Bjarnason NH, Mitlak BH, Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641-7
   PubMed Web of Science ®Google Scholar
• Heaney RP, Recker RR, Omaha PD. Menopausal changes in calcium balance performance. Nutr Rev 1983;41:86-9
   PubMed Web of Science ®Google Scholar
• Recker R, Lappe J, Davies K, Characterization of perimenopausal bone loss: a prospective study. J Bone Miner Res 2000;15:1965-73. 13
   PubMed Web of Science ®Google Scholar
• Akhter MP, Lappe JM, Davies KM, Transmenopausal changes in the trabecular bone structure. Bone 2007;41:111-16
   PubMed Web of Science ®Google Scholar
• Webb P, Lopez GN, Uht RM, Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol Endocrinol 1995;9:443-56
   PubMed Web of Science ®Google Scholar
• Otto C, Wessler S, Fritzemeier KH. Exploiting non genomic estrogen receptor-mediated signaling for the Development of pathway-selective Estrogen receptor ligands. Ernst Schering Found Symp Proc 2006;1:163-81
   Google Scholar
• D'Amelio P, Isaia G. Immune System and Postmenopausal Bone Loss. Clinic Rev Bone Miner Metab 2009;7:262-8
   Google Scholar
• D'Amelio P, Grimaldi A, Di Bella S, Estrogen deficiency increases osteoclastogenesis upregulating T cells activity: a key mechanism in osteoporosis. Bone 2008;43:92-100
   PubMed Web of Science ®Google Scholar
• Grese TA, Sluka JP, Bryant HU, Molecular determinants of tissue selectivity in estrogen receptor modulators. Proc Natl Acad Sci USA 1997;94:14105-10
   PubMed Web of Science ®Google Scholar
• Brzozowski AM, Pike AC, Dauter Z, Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997;389:753-8
   PubMed Web of Science ®Google Scholar
• Kuiper GG, Enmark E, Pelto-Huikko M, Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996;93:5925-30
   PubMed Web of Science ®Google Scholar
• Mosselman S, Polman J, Dijkema R. ERb: identification and characterization of a novel human estrogen receptor. FEBS Lett 1996;392:49-53
   PubMed Web of Science ®Google Scholar
• Paech K, Webb P, Kuiper GG, Differential ligand activation of estrogen receptors ERa and ERb at AP1 sites. Science 1997;277:1508-10
   PubMed Web of Science ®Google Scholar
• Halachmi S, Marden E, Martin G, Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription. Science 1994;264:1455-8
   PubMed Web of Science ®Google Scholar
• Elgort MG, Zou A, Marschke KB, Estrogen and estrogen receptor antagonists stimulate transcription from the human retinoic acid receptor-a1 promoter via a novel sequence. Mol Endocrinol 1996;10:477-87
   PubMed Web of Science ®Google Scholar
• Ozmen B, Kirmaz C, Aydin K, Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis. Eur Cytokine Netw 2007;18:148-53
   PubMed Web of Science ®Google Scholar
• Tu Z, Li H, Ma Y, The enhanced antiproliferative response to combined treatment of trichostatin A with raloxifene in MCF-7 breast cancer cells and its relevance to estrogen receptor beta expression. Mol Cell Biochem 2012;366:111-22
   PubMed Web of Science ®Google Scholar
• Borjesson AE, Windahl SH, Lagerquist MK, Roles of transactivating functions 1 and 2 of estrogen receptor-alpha in bone. Proc Natl Acad Sci USA 2011;108:6288-93
   PubMed Web of Science ®Google Scholar
• Trdan Lusin T, Mrhar A, Stieger B, Influence of hepatic and intestinal efflux transporters and their genetic variants on the pharmacokinetics and pharmacodynamics of raloxifene in osteoporosis treatment. Transl Res 2012;160(4):298-308
   PubMed Web of Science ®Google Scholar
• Boss SM, Huster WJ, Neild JA, Effects of raloxifene hydrochloride on the endometrium of postmenopausal women. Am J Obstet Gynecol 1997;177:1458-64
   PubMed Web of Science ®Google Scholar
• Draper MW, Flowers DE, Huster WJ, A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res 1996;11:835-42
   PubMed Web of Science ®Google Scholar
• Ettinger B, Black DM, Mitlak BH, Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637-45
   PubMed Web of Science ®Google Scholar
• Delmas PD, Ensrud KE, Adachi JD, Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002;87:3609-17
   PubMed Web of Science ®Google Scholar
• Mok CC, Ying KY, To CH, Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial. Ann Rheum Dis 2011;70:778-84
   PubMed Web of Science ®Google Scholar
• Cohen FJ, Lu Y. Characterization of hot flashes reported by healthy postmenopausal women receiving raloxifene or placebo during osteoporosis prevention trials. Maturitas 2000;34:65-73
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Mosca L, Collins P, Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355:125-37
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Mosca L, Collins P, Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355:125-37
   PubMed Web of Science ®Google Scholar
• Cauley JA, Norton L, Lippman ME, Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer Res Treat 2001;65:125-34
   PubMed Web of Science ®Google Scholar
• Martino S, Cauley JA, Barrett-Connor E, CORE Investigators. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004;96:1751-61
   PubMed Web of Science ®Google Scholar
• Veronesi U, Maisonneuve P, Costa A, Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 1998;352:93-7
   PubMed Web of Science ®Google Scholar
• Vogel V, Costantino JP, Wickerham DL, Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes. JAMA 2006;295:2727-41
   PubMed Web of Science ®Google Scholar
• Evista USPI. Available from: http://pi.lilly.com/us/evista-pi.pdf]
   Google Scholar
• Hiligsmann M, Sedrine WB, Reginster JY. Cost-effectiveness of bazedoxifene compared with raloxifene in the treatment of postmenopausal osteoporotic women. J Bone Miner Res 2012; doi: 10.1002/jbmr.1819
   Web of Science ®Google Scholar
• Cummings SR, Ensrud K, Delmas PD, Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med 2010;362:686-96
   PubMed Web of Science ®Google Scholar
• Goldstein SR, Duvernoy CS, Calaf J, Raloxifene use in clinical practice: efficacy and safety. Menopause 2009;16:413-21
   PubMed Web of Science ®Google Scholar
• Collins P, Mosca L, Geiger MJ, Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for The Heart trial: results of subgroup analyses by age and other factors. Circulation 2009;119:922-30
   PubMed Web of Science ®Google Scholar
• Cosman F, Baz-Hecht M, Cushman M, Short-term effects of estrogen tamoxifen and raloxifene on hemostasis: a randomized controlled study and review of the literature. Thromb Res 2005;116:1-13
   PubMed Web of Science ®Google Scholar
• Urushihara H, Kikuchi N, Yamada M, Raloxifene and stroke risks in Japanese postmenopausal women with osteoporosis on postmarketing surveillance. Menopause 2009;16:971-7
   PubMed Web of Science ®Google Scholar
• Iikuni N, Hamaya E, Nihojima S, Safety and effectiveness profile of raloxifene in long-term, prospective, postmarketing surveillance. J Bone Miner Metab 2012;30:674-82
   PubMed Web of Science ®Google Scholar
• Cummings SR, Eckert S, Krueger KA, The effect of raloxifene on risk of breast cancer in postmenopausaIIl women: results from the MORE randomized trial. J Am Med Assoc 1999;281:2189-97
   PubMed Web of Science ®Google Scholar
• Hiligsmann M, Sedrine WB, Reginster JY. Cost-effectiveness of bazedoxifene compared with raloxifene in the treatment of postmenopausal osteoporotic women. J Bone Miner Res 2012; doi: 10.1002/jbmr.1819
   Web of Science ®Google Scholar
• Borgstrom F, Johnell O, Kanis JA, Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Pharmacoeconomics 2004;22(17):1153-65
   PubMed Web of Science ®Google Scholar
• Borgstrom F, Johnell O, Kanis JA, Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Pharmacoeconomics 2004;22:1153-65
   PubMed Web of Science ®Google Scholar
• Schousboe JT, Nyman JA, Kane RL, Ensrud KE. Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women. Ann Intern Med 2005;142:734-41
   PubMed Web of Science ®Google Scholar
• Stevenson M, Jones ML, De Nigris E, A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 2005;9:1-160
   PubMed Web of Science ®Google Scholar
• Strom O, Borgstrom F, Sen SS, Costeffectiveness of alendronate in the treatment of postmenopausal women in 9 European countries — an economic evaluation based on the fracture intervention trial. Osteoporos Int 2007;18:1047-61
   PubMed Web of Science ®Google Scholar
• Kanis JA, McCloskey EV, Johansson H, Case finding for the management of osteoporosis with FRAX — assessment and intervention thresholds for the UK. Osteoporos Int 2008;19:1395-408
   PubMed Web of Science ®Google Scholar
• Ivergard M, Strom O, Borgstrom F, Identifying cost-effective treatment with raloxifene in postmenopausal women using risk algorithms for fractures and invasive breast cancer. Bone 2010;47:966-74
   PubMed Web of Science ®Google Scholar
• Recker RR, Armas L. The effect of antiresorptives on bone quality. Clin Orthop Relat Res 2011;469:2207-14
   PubMed Web of Science ®Google Scholar
• Allen MR, Hogan HA, Hobbs WA, Raloxifene enhances material-level mechanical properties of femoral cortical and trabecular bone. Endocrinology 2007;148:3908-13
   PubMed Web of Science ®Google Scholar
• Cooper C, Reginster JY, Cortet B, Long-term treatment of osteoporosis in postmenopausal women: a review from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF). Curr Med Res Opin 2012;28:475-91
   PubMed Web of Science ®Google Scholar
• Traina TA, Poggesi I, Robson M, Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer. Breast Cancer Res Treat 2008;111:377-88
   PubMed Web of Science ®Google Scholar
• Harris ST, Watts NB, Genant HK, Effects of risedronate treatment on vertebral and non vertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344-52
   PubMed Web of Science ®Google Scholar
• Reginster J, Minne HW, Sorensen OH, Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000;11:83-91
   PubMed Web of Science ®Google Scholar
• Chesnut CH III, Skag A, Christiansen C, Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241-9
   PubMed Web of Science ®Google Scholar
• Meunier PJ, Roux C, Seeman E, The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350(5):459-68
   PubMed Web of Science ®Google Scholar
• Black DM, Cummings SR, Karpf DB, Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures: fracture Intervention Trial Research Group. Lancet 1996;348(9041):1535-41
   PubMed Web of Science ®Google Scholar